Dr. Kimberly R. Kruczek
Claim this profileIngalls Memorial Hospital
Studies Cancer
Studies Squamous Cell Carcinoma
7 reported clinical trials
18 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
PD-L1 negative
2Squamous Cell Carcinoma
Stage IV
PD-L1 positive
PD-L1 negative
Affiliated Hospitals
Clinical Trials Kimberly R. Kruczek is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Nivolumab + Chemotherapy
for Anal Cancer
This trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Recruiting2 awards Phase 321 criteria
More about Kimberly R. Kruczek
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Kimberly R. Kruczek has experience with
- Pembrolizumab
- Carboplatin
- Nivolumab
- Ladiratuzumab Vedotin
- Tisotumab Vedotin
- Cisplatin
Breakdown of trials Kimberly R. Kruczek has run
Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kimberly R. Kruczek specialize in?
Kimberly R. Kruczek focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Kimberly R. Kruczek currently recruiting for clinical trials?
Yes, Kimberly R. Kruczek is currently recruiting for 4 clinical trials in Harvey Illinois. If you're interested in participating, you should apply.
Are there any treatments that Kimberly R. Kruczek has studied deeply?
Yes, Kimberly R. Kruczek has studied treatments such as Pembrolizumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Kimberly R. Kruczek?
Apply for one of the trials that Kimberly R. Kruczek is conducting.
What is the office address of Kimberly R. Kruczek?
The office of Kimberly R. Kruczek is located at: Ingalls Memorial Hospital, Harvey, Illinois 60426 United States. This is the address for their practice at the Ingalls Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.